Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Aceclidine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lenz Therapeutics Launches Vizz In Us Market
    Lenz Therapeutics Launches Vizz In Us Market

    30 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lenz-therapeutics-announces-commercial-product-availability-of-vizz-in-the-united-states-302570157.html

    PR NEWSWIRE
    30 Sep 2025
    Share Share
    Lenz Therapeutics to Present at Investor and Medical Conferences
    Lenz Therapeutics to Present at Investor and Medical Conferences

    25 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/25/3138414/0/en/LENZ-Therapeutics-to-Present-at-Upcoming-Investor-and-Medical-Conferences.html

    GLOBENEWSWIRE
    25 Aug 2025
    Share Share
    LENZ Therapeutics Gets FDA Approval for Presbyopia Treatment VIZZ
    LENZ Therapeutics Gets FDA Approval for Presbyopia Treatment VIZZ

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3125400/0/en/LENZ-Therapeutics-Announces-US-FDA-Approval-of-VIZZ-for-the-Treatment-of-Presbyopia.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    LENZ Therapeutics’s Vizz Receives Approval in US
    LENZ Therapeutics’s Vizz Receives Approval in US

    31 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218585

    FDA
    31 Jul 2025
    Share Share
    LENZ Therapeutics Submits NDA for LNZ100 to NMPA in China
    LENZ Therapeutics Submits NDA for LNZ100 to NMPA in China

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122426/0/en/LENZ-Therapeutics-Announces-NMPA-Submission-of-New-Drug-Application-for-LNZ100-in-China-for-the-Treatment-of-Presbyopia.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    Lenz Therapeutics & Lab Théa Ink Exclusive Deal for Lnz100
    Lenz Therapeutics & Lab Théa Ink Exclusive Deal for Lnz100

    07 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/07/3110985/0/en/LENZ-Therapeutics-and-Laboratoires-Th%C3%A9a-Announce-Exclusive-License-and-Commercialization-Agreement-for-LNZ100-in-Canada.html

    GLOBENEWSWIRE
    07 Jul 2025
    Share Share